

ABOUT THE TEST FoundationOne®Liquid is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating tumor DNA.

PATIENT

DISEASE Colon adenocarcinoma (CRC)
 NAME Not Given
 DATE OF BIRTH Not Given
 SEX Not Given
 MEDICAL RECORD # Not Given

PHYSICIAN

ORDERING PHYSICIAN Not Given
 MEDICAL FACILITY Not Given
 ADDITIONAL RECIPIENT Not Given
 MEDICAL FACILITY ID Not Given
 PATHOLOGIST Not Given

SPECIMEN

SPECIMEN ID Not Given
 SPECIMEN TYPE Blood
 DATE OF COLLECTION Not Given
 SPECIMEN RECEIVED Not Given
 MEDIAN EXON COVERAGE 4,000x

Biomarker Findings
Microsatellite status MSI-High
Genomic Findings
For a complete list of the genes assayed, please refer to the Appendix.

KRAS G12D
PIK3CA C420R
PTEN P96S, R233*
APC D849fs*2, S1465fs*9

2 Therapies with Clinical Benefit
 2 Therapies with Lack of Response

37 Clinical Trials

BIOMARKER FINDINGS
Microsatellite status - MSI-High

10 Trials see p. 9

GENOMIC FINDINGS
MAF %

KRAS - G12D 19.16%

7 Trials see p. 11

PIK3CA - C420R 5.1%

10 Trials see p. 12

PTEN - P96S 7.3%

R233* 0.14%

10 Trials see p. 14

**THERAPIES WITH CLINICAL BENEFIT
(IN PATIENT'S TUMOR TYPE)**

Nivolumab

Pembrolizumab

**THERAPIES WITH CLINICAL BENEFIT
(IN PATIENT'S TUMOR TYPE)**

 ▲ Cetuximab¹

 ▲ Panitumumab¹
**THERAPIES WITH CLINICAL BENEFIT
(IN OTHER TUMOR TYPE)**

none

**THERAPIES WITH CLINICAL BENEFIT
(IN OTHER TUMOR TYPE)**

none

▲ 1. Patient may be resistant to indicated therapy

CRF# XXXXXXXX

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.


APC - D849fs*2, S1465fs*9 p. 5

NOTE Genomic alterations detected may be associated with activity of certain FDA-approved drugs; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. In the appropriate clinical context, germline testing of *APC*, *BRCA1*, *BRCA2*, *CDH1*, *NF1*, *PALB2*, *RBI*, *RET*, *STK11*, and *TP53* is recommended.

Mutant Allele Frequency is not applicable for copy number amplifications or rearrangements.

SAMPLE

CRF# XXXXXXXX



HISTORIC PATIENT FINDINGS		TEST 1
Microsatellite status		MSI-High
KRAS	● G12D	19.16%
PIK3CA	● C420R	5.1%
PTEN	● P96S	7.3%
	● R233*	0.14%%
APC	● D849fs*2	17.3%
	● S1465fs*9	25.1%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid or FoundationOne® tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.